Preclinical studies using Cop-1 have demonstrated that after daily administration for 7 days in a murine PD model, mice presented a decrease in midbrain α-Synuclein and microglial marker allograft inflammatory factor 1 (AIF1) levels, an increase in BDNF levels and the animals had an improvement in motor functions, particularly gait and grip strength [51]. Here, AIF1 is linked to Parkinson disease.